Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?. Issue 6 (December 2022)

• Record Type: Journal Article
• Authors: Gattuso, Giovanna; Schiavello, Elisabetta; Oltolini, Chiara; Biassoni, Veronica; Terenziani, Monica; Chiaravalli, Stefano; Podda, Marta Giorgia; Meazza, Cristina; Luksch, Roberto; Ferrari, Andrea; Casanova, Michela; Sironi, Giovanna; Bergamaschi, Luca; Puma, Nadia; Spreafico, Filippo; Massimino, Maura
• Is Part Of: Tumori. Volume 108:Issue 6(2022)
• Page Start: NP1
• Page End: NP4
• Publication Date: 2022-12
• Subjects: COVID-19 -- lymphoma -- prolonged infection -- treatments; Cancer -- Periodicals; 616.994
• DOI: 10.1177/03008916211067825
• Languages: English
• ISSNs: 0300-8916

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, oncologists have managed patients at higher risk of having a severe course of this infection. This raises new questions about their correct management, as well as the difficulty of distinguishing tumor/treatments complications from those related to COVID-19. We report a case of an 11-year-old boy undergoing treatment for T-cell lymphoblastic lymphoma who experienced a prolonged COVID-19 course. Oncologic therapy was continued without significant changes compared to the initially planned treatment. No relevant complications occurred. COVID-19 convalescent plasma was administered, resulting in a positive antibody titer after 24 days.